BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterology 2003;98:2485-90. [DOI: 10.1111/j.1572-0241.2003.08699.x] [Cited by in Crossref: 476] [Cited by in F6Publishing: 409] [Article Influence: 25.1] [Reference Citation Analysis]
Number Citing Articles
1 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
2 Licata A, Zerbo M, Como S, Cammilleri M, Soresi M, Montalto G, Giannitrapani L. The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement? Nutrients 2021;13:4014. [PMID: 34836267 DOI: 10.3390/nu13114014] [Reference Citation Analysis]
3 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
4 Yu SJ, Bae S, Kang JS, Yoon J, Cho EJ, Lee J, Kim YJ, Lee WJ, Kim CY, Lee H. Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo(−/−) mice. European Journal of Pharmacology 2015;762:247-55. [DOI: 10.1016/j.ejphar.2015.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
5 Devendrachari MC, Thimmappa R, Bhat ZM, Shafi SP, Nimbegondi Kotresh HM, Kottaichamy AR, Venugopala Reddy KR, Thotiyl MO. A vitamin C fuel cell with a non-bonded cathodic interface. Sustainable Energy Fuels 2018;2:1813-9. [DOI: 10.1039/c8se00221e] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Horoz M, Bolukbas C, Bolukbas FF, Sabuncu T, Aslan M, Sarifakiogullari S, Gunaydin N, Erel O. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005;5:35. [PMID: 16283935 DOI: 10.1186/1471-230X-5-35] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
7 Chitturi S. Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol 2008;1:173-89. [PMID: 21180527 DOI: 10.1177/1756283X08096951] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
8 Webster CR, Cooper J. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease. Vet Clin North Am Small Anim Pract 2009;39:631-52. [PMID: 19524797 DOI: 10.1016/j.cvsm.2009.02.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
9 Villalpando-Arteaga EV, Mendieta-Condado E, Esquivel-Solís H, Canales-Aguirre AA, Gálvez-Gastélum FJ, Mateos-Díaz JC, Rodríguez-González JA, Márquez-Aguirre AL. Hibiscus sabdariffa L. aqueous extract attenuates hepatic steatosis through down-regulation of PPAR-γ and SREBP-1c in diet-induced obese mice. Food Funct 2013;4:618-26. [PMID: 23389749 DOI: 10.1039/c3fo30270a] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
10 Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011;106:71-7. [PMID: 20842109 DOI: 10.1038/ajg.2010.299] [Cited by in Crossref: 171] [Cited by in F6Publishing: 156] [Article Influence: 14.3] [Reference Citation Analysis]
11 Reidling JC, Rubin SA. Promoter analysis of the human ascorbic acid transporters SVCT1 and 2: mechanisms of adaptive regulation in liver epithelial cells. J Nutr Biochem 2011;22:344-50. [PMID: 20471816 DOI: 10.1016/j.jnutbio.2010.03.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
12 Murer SB, Aeberli I, Braegger CP, Gittermann M, Hersberger M, Leonard SW, Taylor AW, Traber MG, Zimmermann MB. Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents. J Nutr 2014;144:193-201. [PMID: 24353344 DOI: 10.3945/jn.113.185561] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
13 Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365 [PMID: 24966606 DOI: 10.3748/wjg.v20.i23.7356] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
14 Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis. 2012;16:631-645. [PMID: 22824485 DOI: 10.1016/j.cld.2012.05.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
15 Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28. [PMID: 18537181 DOI: 10.1002/hep.22336] [Cited by in Crossref: 272] [Cited by in F6Publishing: 243] [Article Influence: 19.4] [Reference Citation Analysis]
16 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 113] [Reference Citation Analysis]
17 Zamin I Jr, Mattos AA, Mattos AZ, Coral G, Santos D, Rhoden C. The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. Arq Gastroenterol 2010;47:86-92. [PMID: 20520981 DOI: 10.1590/s0004-28032010000100015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
18 Sumida Y, Yoneda M, Seko Y, Takahashi H, Hara N, Fujii H, Itoh Y, Yoneda M, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD). Role of vitamin E in the treatment of non-alcoholic steatohepatitis. Free Radic Biol Med 2021;177:391-403. [PMID: 34715296 DOI: 10.1016/j.freeradbiomed.2021.10.017] [Reference Citation Analysis]
19 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
20 Zingg J. Vitamin E: An overview of major research directions. Molecular Aspects of Medicine 2007;28:400-22. [DOI: 10.1016/j.mam.2007.05.004] [Cited by in Crossref: 132] [Cited by in F6Publishing: 88] [Article Influence: 8.8] [Reference Citation Analysis]
21 Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention. J Surg Res. 2011;167:96-112. [PMID: 20400112 DOI: 10.1016/j.jss.2009.10.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
22 Subramanian VS, Srinivasan P, Wildman AJ, Marchant JS, Said HM. Molecular mechanism(s) involved in differential expression of vitamin C transporters along the intestinal tract. Am J Physiol Gastrointest Liver Physiol 2017;312:G340-7. [PMID: 27932501 DOI: 10.1152/ajpgi.00369.2016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
23 Said A, Akhter A. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. Ann Hepatol. 2017;16:538-547. [PMID: 28611274 DOI: 10.5604/01.3001.0010.0284] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 12.5] [Reference Citation Analysis]
24 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
25 Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:679-692. [PMID: 20415840 DOI: 10.1111/j.1365-2036.2009.04230.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 73] [Article Influence: 10.6] [Reference Citation Analysis]
26 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
27 Subramanian VS, Marchant JS, Said HM. Molecular determinants dictating cell surface expression of the human sodium-dependent vitamin C transporter-2 in human liver cells. Am J Physiol Gastrointest Liver Physiol 2010;298:G267-74. [PMID: 19926816 DOI: 10.1152/ajpgi.00435.2009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
28 Mullin GE. Vitamin E for Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2011;26:636-7. [DOI: 10.1177/0884533611418343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004] [Cited by in Crossref: 434] [Cited by in F6Publishing: 426] [Article Influence: 27.1] [Reference Citation Analysis]
30 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
31 Orlando R, Azzalini L, Orando S, Lirussi F; Cochrane Hepato-Biliary Group. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd005160.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
32 Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20(10): 2515-2532 [PMID: 24627588 DOI: 10.3748/wjg.v20.i10.2515] [Cited by in CrossRef: 190] [Cited by in F6Publishing: 176] [Article Influence: 23.8] [Reference Citation Analysis]
33 Adams LA, Angulo P. Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers. Clin Gastroenterol Hepatol. 2004;2:1059-1060. [PMID: 15625648 DOI: 10.1016/s1542-3565(04)00462-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
34 Khoshbaten M, Aliasgarzadeh A, Masnadi K, Farhang S, Tarzamani MK, Babaei H, Kiani J, Zaare M, Najafipoor F. Grape seed extract to improve liver function in patients with nonalcoholic fatty liver change. Saudi J Gastroenterol 2010;16:194-7. [PMID: 20616415 DOI: 10.4103/1319-3767.65197] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
35 Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). J Clin Transl Hepatol 2021;9:939-46. [PMID: 34966657 DOI: 10.14218/JCTH.2021.00189] [Reference Citation Analysis]
36 Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:148-155. [PMID: 16265156 DOI: 10.1038/ncpgasthep0116] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.7] [Reference Citation Analysis]
37 Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol. 2007;22:2009-2014. [PMID: 17914984 DOI: 10.1111/j.1440-1746.2006.04681.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
38 Ji HF, Sun Y, Shen L. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.Nutrition. 2014;30:986-991. [PMID: 24976430 DOI: 10.1016/j.nut.2014.01.016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
39 Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology 2017;11:357-69. [DOI: 10.1080/17474124.2017.1293523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
40 Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J 2018;94:556-65. [PMID: 30341231 DOI: 10.1136/postgradmedj-2018-135967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
41 Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4:391-417. [PMID: 22043231 DOI: 10.1177/1756283x11413002] [Cited by in Crossref: 141] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
42 Spahis S, Delvin E, Borys JM, Levy E. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxid Redox Signal. 2017;26:519-541. [PMID: 27452109 DOI: 10.1089/ars.2016.6776] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 28.8] [Reference Citation Analysis]
43 Richter K, Kietzmann T. Reactive oxygen species and fibrosis: further evidence of a significant liaison. Cell Tissue Res 2016;365:591-605. [PMID: 27345301 DOI: 10.1007/s00441-016-2445-3] [Cited by in Crossref: 129] [Cited by in F6Publishing: 123] [Article Influence: 21.5] [Reference Citation Analysis]
44 Xu Y, Wu Y, Xiong Y, Tao J, Pan T, Tan S, Gao G, Chen Y, Abbas N, Getachew A, Zhuang Y, You K, Yang F, Li YX. Ascorbate protects liver from metabolic disorder through inhibition of lipogenesis and suppressor of cytokine signaling 3 (SOCS3). Nutr Metab (Lond) 2020;17:17. [PMID: 32158492 DOI: 10.1186/s12986-020-0431-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17:1379. [PMID: 27563875 DOI: 10.3390/ijms17091379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
46 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2009.12.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
47 Dichtel LE, Eajazi A, Miller KK, Torriani M, Bredella MA. Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity. J Comput Assist Tomogr 2016;40:678-82. [PMID: 27116479 DOI: 10.1097/RCT.0000000000000423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
48 Valatas V, Filidou E, Drygiannakis I, Kolios G. Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface. Ann Gastroenterol 2017;30:393-404. [PMID: 28655975 DOI: 10.20524/aog.2017.0146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
49 Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of “second hit”. World J Gastroenterol 2013; 19(8): 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 96] [Article Influence: 11.1] [Reference Citation Analysis]
50 Salehi-Sahlabadi A, Mokari A, Elhamkia M, Farahmand F, Jabbari M, Hekmatdost A. Dietary Total Antioxidant Capacity and Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. J Res Health Sci 2020;20:e00486. [PMID: 33169718 DOI: 10.34172/jrhs.2020.18] [Reference Citation Analysis]
51 Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90. [PMID: 15842582 DOI: 10.1111/j.1572-0241.2005.41583.x] [Cited by in Crossref: 473] [Cited by in F6Publishing: 413] [Article Influence: 27.8] [Reference Citation Analysis]
52 Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008;19:491-504. [PMID: 17855068 DOI: 10.1016/j.jnutbio.2007.06.011] [Cited by in Crossref: 189] [Cited by in F6Publishing: 166] [Article Influence: 12.6] [Reference Citation Analysis]
53 Hickman I, Macdonald G. Is vitamin E beneficial in chronic liver disease? Hepatology 2007;46:288-90. [DOI: 10.1002/hep.21834] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
54 Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015;62:1417-1432. [PMID: 26189925 DOI: 10.1002/hep.27999] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 14.1] [Reference Citation Analysis]
55 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
56 Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O, Tsunematsu S, Morinaga S, Tsuchimoto K. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2008;23:1909-1916. [PMID: 18422963 DOI: 10.1111/j.1440-1746.2008.05393.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
57 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
58 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
59 Aguilera-mendez A, Hernández-equihua MG, Rueda-rocha AC, Guajardo-lópez C, Nieto-aguilar R, Serrato-ochoa D, Ruíz Herrera LF, Guzmán-nateras JA. Protective effect of supplementation with biotin against high-fructose-induced metabolic syndrome in rats. Nutrition Research 2018;57:86-96. [DOI: 10.1016/j.nutres.2018.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
60 Zamin Jr. I, Mattos AAD, Mattos ÂZD, Migon E, Soares E, Perry MLS. Modelo experimental de esteatohepatite não-alcoólica com dieta deficiente em metionina e colina. Arq Gastroenterol 2009;46:69-74. [DOI: 10.1590/s0004-28032009000100017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
61 Lakhani HV, Sharma D, Dodrill MW, Nawab A, Sharma N, Cottrill CL, Shapiro JI, Sodhi K. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease. Int J Med Sci 2018;15:1591-9. [PMID: 30588181 DOI: 10.7150/ijms.27953] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
62 Jansen PL. Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2004;16:1079-1085. [PMID: 15489564 DOI: 10.1097/00042737-200411000-00001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
63 Mendes FD, Lindor KD. Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opinion on Investigational Drugs 2005;14:29-35. [DOI: 10.1517/13543784.14.1.29] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
64 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
65 Uetake Y, Ikeda H, Irie R, Tejima K, Matsui H, Ogura S, Wang H, Mu S, Hirohama D, Ando K, Sawamura T, Yatomi Y, Fujita T, Shimosawa T. High-salt in addition to high-fat diet may enhance inflammation and fibrosis in liver steatosis induced by oxidative stress and dyslipidemia in mice. Lipids Health Dis 2015;14:6. [PMID: 25888871 DOI: 10.1186/s12944-015-0002-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
66 Wilbur K. Nonviral Hepatitis. Journal of Pharmacy Practice 2009;22:388-404. [DOI: 10.1177/0897190008328694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Pimentel CF, Lai M. Nutrition Interventions for Chronic Liver Diseases and Nonalcoholic Fatty Liver Disease. Med Clin North Am. 2016;100:1303-1327. [PMID: 27745596 DOI: 10.1016/j.mcna.2016.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
68 Reidling JC, Subramanian VS, Dahhan T, Sadat M, Said HM. Mechanisms and regulation of vitamin C uptake: studies of the hSVCT systems in human liver epithelial cells. Am J Physiol Gastrointest Liver Physiol 2008;295:G1217-27. [PMID: 18845575 DOI: 10.1152/ajpgi.90399.2008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
69 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
70 Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV. Systematic review: hepatic fibrosis - regression with therapy. Aliment Pharmacol Ther 2008;28:1175-87. [PMID: 18761707 DOI: 10.1111/j.1365-2036.2008.03840.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
71 Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, Chiu CC, Chuang WL, Tsai TR, Yu ML. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22:2118-2123. [PMID: 18031368 DOI: 10.1111/j.1440-1746.2006.04698.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis]
72 Ota T. Prevention of NAFLD/NASH by Astaxanthin and β-Cryptoxanthin. Adv Exp Med Biol 2021;1261:231-8. [PMID: 33783746 DOI: 10.1007/978-981-15-7360-6_21] [Reference Citation Analysis]
73 Gianturco V, Troisi G, Bellomo A, Bernardini S, D'Ottavio E, Formosa V, Iacono CL, Verrusio W, Marigliano B, Marigliano V. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hepatol Int 2013;7:570-6. [PMID: 26201789 DOI: 10.1007/s12072-012-9387-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
74 Tang JT, Mao YM. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence: Pharmacotherapy of NASH. Journal of Digestive Diseases 2017;18:607-17. [DOI: 10.1111/1751-2980.12557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:923-930. [PMID: 26059365 DOI: 10.1016/j.nut.2014.11.018] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 11.5] [Reference Citation Analysis]
76 Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8:25-30. [PMID: 18366995 DOI: 10.1007/s11892-008-0006-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
77 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
78 Paredes AH, Torres DM, Harrison SA. Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2012;16:397-419. [DOI: 10.1016/j.cld.2012.03.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
79 Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol. 2007;42:139-147. [PMID: 17327932 DOI: 10.1080/00365520601058395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
80 Tsou P, Wu CJ. Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. J Clin Med 2019;8:E1057. [PMID: 31330971 DOI: 10.3390/jcm8071057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
81 Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong JW, Khan NA, Abu Bakar MR, Ng BH, Yuen KH. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J. 2013;12:166. [PMID: 24373555 DOI: 10.1186/1475-2891-12-166] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
82 Tseng S, Chien T, Tzeng C, Lin Y, Wu C, Wang C. Prevention of hepatic oxidative injury by Xiao-Chen-Chi-Tang in mice. Journal of Ethnopharmacology 2007;111:232-9. [DOI: 10.1016/j.jep.2006.11.030] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
83 Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-725.e6. [PMID: 22326434 DOI: 10.1053/j.gastro.2012.02.003] [Cited by in Crossref: 482] [Cited by in F6Publishing: 450] [Article Influence: 48.2] [Reference Citation Analysis]
84 Xiao J, Guo R, Fung ML, Liong EC, Tipoe GL. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int. 2013;12:125-135. [PMID: 23558065 DOI: 10.1016/s1499-3872(13)60021-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
85 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 13.4] [Reference Citation Analysis]
86 Sanchez-Pareja A, Clément S, Peyrou M, Spahr L, Negro F, Rubbia-Brandt L, Foti M. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. World J Gastroenterol 2016; 22(14): 3735-3745 [PMID: 27076758 DOI: 10.3748/wjg.v22.i14.3735] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
87 Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846-858 [PMID: 25937862 DOI: 10.4254/wjh.v7.i6.846] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 23.7] [Reference Citation Analysis]
88 Comar KM, Sterling RK. Review article: Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;23:207-215. [PMID: 16393299 DOI: 10.1111/j.1365-2036.2006.02751.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
89 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
90 Gan SK, Adams LA, Watts GF. The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. Current Opinion in Lipidology 2008;19:592-9. [DOI: 10.1097/mol.0b013e328317cc42] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
91 McNear S, Harrison SA. Current status of therapy in nonalcoholic Fatty liver disease. Therap Adv Gastroenterol. 2009;2:29-43. [PMID: 21180532 DOI: 10.1177/1756283x08100327] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
92 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 304] [Cited by in F6Publishing: 267] [Article Influence: 60.8] [Reference Citation Analysis]
93 Subramanian VS, Marchant JS, Reidling JC, Said HM. N-Glycosylation is required for Na+-dependent vitamin C transporter functionality. Biochem Biophys Res Commun 2008;374:123-7. [PMID: 18619416 DOI: 10.1016/j.bbrc.2008.06.120] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
94 Vahid F, Rahmani D, Hekmatdoost A. The association between dietary antioxidant index (DAI) and nonalcoholic fatty liver disease (NAFLD) onset; new findings from an incident case-control study. Clin Nutr ESPEN 2021;41:360-4. [PMID: 33487290 DOI: 10.1016/j.clnesp.2020.10.020] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
95 Agrawal S, Daruwala C. Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford). 2011;13:846-859. [PMID: 22081919 DOI: 10.1111/j.1477-2574.2011.00380.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
96 Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-22. [PMID: 16679470 DOI: 10.1136/pgmj.2005.042200] [Cited by in Crossref: 165] [Cited by in F6Publishing: 148] [Article Influence: 10.3] [Reference Citation Analysis]
97 Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A, Del Rosario Abreu Vazquez M. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009;30:999-1009. [PMID: 19691668 DOI: 10.1111/j.1365-2036.2009.04122.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 5.2] [Reference Citation Analysis]
98 Wiegand J, Mössner J, Tillmann HL. [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis]. Internist (Berl) 2007;48:154-63. [PMID: 17226007 DOI: 10.1007/s00108-006-1796-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
99 Caldwell S. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol 2017;23:103-8. [PMID: 28494529 DOI: 10.3350/cmh.2017.0103] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
100 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
101 Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014;15:2501-11. [DOI: 10.1517/14656566.2014.960389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
102 Serviddio G, Bellanti F, Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med. 2013;65:952-968. [PMID: 23994574 DOI: 10.1016/j.freeradbiomed.2013.08.174] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 14.8] [Reference Citation Analysis]
103 Yunianingtias D, Volker D. Nutritional aspects of non-alcoholic steatohepatitis treatment. Nutrition & Dietetics 2006;63:79-90. [DOI: 10.1111/j.1747-0080.2006.00054.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
104 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY, Mao YM. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008;9:108-112. [PMID: 18419645 DOI: 10.1111/j.1751-2980.2008.00331.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 120] [Article Influence: 8.1] [Reference Citation Analysis]
106 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Ko JS. Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2010;56:6. [DOI: 10.4166/kjg.2010.56.1.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
108 Ratziu V, Zelber-sagi S. Pharmacologic Therapy of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:667-88. [DOI: 10.1016/j.cld.2009.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
109 Ozel Coskun BD, Yucesoy M, Gursoy S, Baskol M, Yurci A, Yagbasan A, Doğan S, Baskol G. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2015;27:142-9. [PMID: 25533429 DOI: 10.1097/MEG.0000000000000264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
110 Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children. Clinical Nutrition 2007;26:409-15. [DOI: 10.1016/j.clnu.2007.02.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
111 Frankel RA, Michels KA, Kim K, Kuhr DL, Omosigho UR, Wactawski-Wende J, Levine L, Perkins NJ, Mumford SL. Serum antioxidant vitamin concentrations and oxidative stress markers associated with symptoms and severity of premenstrual syndrome: a prospective cohort study. BMC Womens Health 2021;21:49. [PMID: 33530988 DOI: 10.1186/s12905-021-01187-7] [Reference Citation Analysis]
112 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am. 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2004.12.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
113 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
114 El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel) 2018;7:E12. [PMID: 29337849 DOI: 10.3390/antiox7010012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
115 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
116 Martín-pozuelo G, Navarro-gonzález I, González-barrio R, Santaella M, García-alonso J, Hidalgo N, Gómez-gallego C, Ros G, Periago MJ. The effect of tomato juice supplementation on biomarkers and gene expression related to lipid metabolism in rats with induced hepatic steatosis. Eur J Nutr 2015;54:933-44. [DOI: 10.1007/s00394-014-0770-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
117 Nobili V, Manco M. Therapeutic strategies for pediatric non-alcoholic fatty liver disease: A challenge for health care providers. World J Gastroenterol 2007; 13(18): 2639-2641 [PMID: 17552019 DOI: 10.3748/wjg.v13.i18.2639] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
118 Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol. 2005;39:619-625. [PMID: 16000931 DOI: 10.1097/00004836-200508000-00012] [Cited by in Crossref: 190] [Cited by in F6Publishing: 169] [Article Influence: 11.2] [Reference Citation Analysis]
119 Pai RK, Kleiner DE, Hart J, Adeyi OA, Clouston AD, Behling CA, Jain D, Kakar S, Brahmania M, Burgart L, Batts KP, Valasek MA, Torbenson MS, Guindi M, Wang HL, Ajmera V, Adams LA, Parker CE, Feagan BG, Loomba R, Jairath V. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther 2019;50:1100-11. [PMID: 31583739 DOI: 10.1111/apt.15503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
120 Corrado RL, Torres DM, Harrison SA. Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 2014;98:55-72. [DOI: 10.1016/j.mcna.2013.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
121 Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014;2014:637027. [PMID: 25371775 DOI: 10.1155/2014/637027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
122 Moreno Sánchez D. Tratamiento médico de la hepatopatía grasa no alcohólica primaria. Medicina Clínica 2005;125:108-16. [DOI: 10.1157/13076737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
123 Bémeur C, Desjardins P, Butterworth RF. Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J Nutr Metab. 2010;2010:489823. [PMID: 21234351 DOI: 10.1155/2010/489823] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
124 Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver. 2016;10:177-203. [PMID: 26934884 DOI: 10.5009/gnl15352] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 11.7] [Reference Citation Analysis]
125 Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol 2021;2021:6613827. [PMID: 33681089 DOI: 10.1155/2021/6613827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine 2012;52:59-69. [DOI: 10.1016/j.freeradbiomed.2011.10.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 519] [Article Influence: 53.9] [Reference Citation Analysis]
127 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
128 Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int 2021;41:982-95. [PMID: 33283415 DOI: 10.1111/liv.14749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2006; 12(14): 2161-2167 [PMID: 16610015 DOI: 10.3748/wjg.v12.i14.2161] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
130 Zhang D, Xie L, Jia G, Cai S, Ji B, Liu Y, Wu W, Zhou F, Wang A, Chu L, Wei Y, Liu J, Gao F. Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro. Eur J Med Chem 2011;46:4548-58. [PMID: 21824690 DOI: 10.1016/j.ejmech.2011.07.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
131 Harrison SA, Neuschwander-tetri BA. Pharmacologic management of nonalcoholic fatty liver disease. Clinics in Liver Disease 2004;8:715-28. [DOI: 10.1016/j.cld.2004.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
132 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
133 Lv H, Wang C, Fang T, Li T, Lv G, Han Q, Yang W, Wang H. Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2. NPJ Precis Oncol 2018;2:1. [PMID: 29872720 DOI: 10.1038/s41698-017-0044-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
134 Silva LGDOE, Manso JEF, Silva RARND, Pereira SE, Saboya Sobrinho CJ, Rangel CW. Relação entre o estado nutricional de vitamina a e a regressão da esteatose hepática após gastroplastia em Y- de- Roux para tratamento da obesidade classe III. ABCD, arq bras cir dig 2012;25:250-6. [DOI: 10.1590/s0102-67202012000400008] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
135 Soylu AR, Altaner S, Aydodu N, Basaran UN, Tarcin O, Gedik N, Umit H, Tezel A, Ture M, Kutlu K, Kaymak K. Effects of vitamins E and C supplementation on hepatic glutathione peroxidase activity and tissue injury associated with ethanol ingestion in malnourished rats. Curr Ther Res Clin Exp. 2006;67:118-137. [PMID: 24678089 DOI: 10.1016/j.curtheres.2006.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
136 Ciebiera M, Ali M, Zgliczyńska M, Skrzypczak M, Al-Hendy A. Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance. Int J Mol Sci 2020;21:E5528. [PMID: 32752274 DOI: 10.3390/ijms21155528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
137 Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Annals of Hepatology 2009;8:S51-9. [DOI: 10.1016/s1665-2681(19)31827-7] [Cited by in Crossref: 26] [Article Influence: 2.0] [Reference Citation Analysis]
138 Kondo Y, Hasegawa G, Okada H, Senmaru T, Fukui M, Nakamura N, Sawada M, Kitawaki J, Okanoue T, Kishimoto Y, Amano A, Maruyama N, Obayashi H, Ishigami A. Lepr(db/db) Mice with senescence marker protein-30 knockout (Lepr(db/db)Smp30(Y/-)) exhibit increases in small dense-LDL and severe fatty liver despite being fed a standard diet. PLoS One 2013;8:e65698. [PMID: 23755269 DOI: 10.1371/journal.pone.0065698] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
139 Roberts EA, Yap J. Nonalcoholic fatty liver disease (NAFLD): Approach in the adolescent patient. Curr Treat Options Gastro 2006;9:423-31. [DOI: 10.1007/bf02738532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
140 Fuda H, Watanabe M, Hui S, Joko S, Okabe H, Jin S, Takeda S, Miki E, Watanabe T, Chiba H. Anti-apoptotic effects of novel phenolic antioxidant isolated from the Pacific oyster (Crassostrea gigas) on cultured human hepatocytes under oxidative stress. Food Chemistry 2015;176:226-33. [DOI: 10.1016/j.foodchem.2014.12.066] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
141 Miyazaki H, Takitani K, Koh M, Yoden A, Tamai H. The α-tocopherol status and expression of α-tocopherol-related proteins in methionine-choline deficient rats treated with vitamin E. J Clin Biochem Nutr 2014;54:190-7. [PMID: 24895482 DOI: 10.3164/jcbn.13-74] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
142 de Piano A, Prado WL, Caranti DA, Siqueira KO, Stella SG, Lofrano M, Tock L, Cristofalo DM, Lederman H, Tufik S, de Mello MT, Dâmaso AR. Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2007;44:446-52. [PMID: 17414142 DOI: 10.1097/MPG.0b013e31803815d9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
143 Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006;40:930-935. [PMID: 17063114 DOI: 10.1097/01.mcg.0000212608.59090.08] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 6.3] [Reference Citation Analysis]
144 Hoteit MA, Anania FA. Treatment of fibrosis in nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2007;9:47-53. [PMID: 17335677 DOI: 10.1007/s11894-008-0020-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
145 Musso G, Gambino R, De Michieli F, Premoli A, Biroli G, Fagà E, Pagano G, Cassader M, Durazzo M. The Postprandial Phase as a Link Between Systemic Lipid Peroxidation and Liver Injury in NASH This article has been retracted. Am J Gastroenterology 2006;0:061113084836024-???. [DOI: 10.1111/j.1572-0241.2006.00794.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013; 4(3): 51-63 [PMID: 23772273 DOI: 10.4239/wjd.v4.i3.51] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
147 Harrison SA. New treatments for nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2006;8:21-29. [PMID: 16510031 DOI: 10.1007/s11894-006-0060-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
148 Ramírez-Vélez R, García-Hermoso A, Izquierdo M, Correa-Rodríguez M. The Dietary Inflammatory Index and hepatic health in the US adult population. J Hum Nutr Diet 2021. [PMID: 34783091 DOI: 10.1111/jhn.12962] [Reference Citation Analysis]
149 Duvnjak M, Lerotić I, Baršić N, Tomašić V, Jukić LV, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13(34): 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539] [Cited by in CrossRef: 157] [Cited by in F6Publishing: 142] [Article Influence: 10.5] [Reference Citation Analysis]
150 Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905. [PMID: 15795412 DOI: 10.1503/cmaj.045232] [Cited by in Crossref: 330] [Cited by in F6Publishing: 313] [Article Influence: 19.4] [Reference Citation Analysis]
151 Li YH, Yang LH, Sha KH, Liu TG, Zhang LG, Liu XX. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(22): 7008-7013 [PMID: 26078579 DOI: 10.3748/wjg.v21.i22.7008] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
152 Hwang YC, Oh DH, Choi MC, Lee SY, Ahn KJ, Chung HY, Lim SJ, Chung SH, Jeong IK. Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats. Korean J Intern Med 2018;33:347-55. [PMID: 28142230 DOI: 10.3904/kjim.2015.208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
153 Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88-96. [PMID: 18804555 DOI: 10.1016/j.cct.2008.09.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
154 Rahmani J, Miri A, Namjoo I, Zamaninour N, Maljaei MB, Zhou K, Cerneviciute R, Mousavi SM, Varkaneh HK, Salehisahlabadi A, Zhang Y. Elevated liver enzymes and cardiovascular mortality: a systematic review and dose-response meta-analysis of more than one million participants. Eur J Gastroenterol Hepatol 2019;31:555-62. [PMID: 30614883 DOI: 10.1097/MEG.0000000000001353] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
155 Athinarayanan S, Wei R, Zhang M, Bai S, Traber MG, Yates K, Cummings OW, Molleston J, Liu W, Chalasani N. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. PLoS One. 2014;9:e95366. [PMID: 24759732 DOI: 10.1371/journal.pone.0095366] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
156 Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011640. [PMID: 28358980 DOI: 10.1002/14651858.CD011640.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
157 Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45): 16841-16857 [PMID: 25492998 DOI: 10.3748/wjg.v20.i45.16841] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
158 Adrian JE, Poelstra K, Kamps JA. Addressing liver fibrosis with liposomes targeted to hepatic stellate cells. J Liposome Res. 2007;17:205-218. [PMID: 18027241 DOI: 10.1080/08982100701528047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
159 Ued Fda V, Weffort VR. Antioxidant vitamins in the context of nonalcoholic fatty liver disease in obese children and adolescents. Rev Paul Pediatr 2013;31:523-30. [PMID: 24473959 DOI: 10.1590/S0103-05822013000400016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
161 Lee JY, Im AR, Shim KS, Ji KY, Kim KM, Kim YH, Chae S. Beneficial Effects of Insect Extracts on Nonalcoholic Fatty Liver Disease. J Med Food 2020;23:760-71. [PMID: 32380876 DOI: 10.1089/jmf.2019.4536] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009;16:141-149. [PMID: 19262374 DOI: 10.1097/med.0b013e3283293015] [Cited by in Crossref: 114] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
163 Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335. [PMID: 16355018 DOI: 10.1097/00000441-200512000-00011] [Cited by in Crossref: 128] [Cited by in F6Publishing: 125] [Article Influence: 8.0] [Reference Citation Analysis]
164 Tanaka H, Fukahori S, Baba S, Ueno T, Sivakumar R, Yagi M, Asagiri K, Ishii S, Tanaka Y. Branched-Chain Amino Acid-Rich Supplements Containing Microelements Have Antioxidant Effects on Nonalcoholic Steatohepatitis in Mice. JPEN J Parenter Enteral Nutr. 2016;40:519-528. [PMID: 25316683 DOI: 10.1177/0148607114555160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
165 Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017; 8(2): 67-76 [PMID: 28573069 DOI: 10.4291/wjgp.v8.i2.67] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
166 Subramanian VS, Sabui S, Marchant JS, Said HM. MicroRNA-103a regulates sodium-dependent vitamin C transporter-1 expression in intestinal epithelial cells. J Nutr Biochem 2019;65:46-53. [PMID: 30616065 DOI: 10.1016/j.jnutbio.2018.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
167 Alvarellos ML, Sangkuhl K, Daneshjou R, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for CYP4F2. Pharmacogenet Genomics 2015;25:41-7. [PMID: 25370453 DOI: 10.1097/FPC.0000000000000100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
168 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
169 Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Emerging drugs for non-alcoholic steatohepatitis. Expert Opin Emerg Drugs. 2013;18:279-290. [PMID: 23848366 DOI: 10.1517/14728214.2013.811232] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
170 Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006;24:1553-61. [DOI: 10.1111/j.1365-2036.2006.03161.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 7.3] [Reference Citation Analysis]
171 Satapathy SK, Sanyal AJ. Novel treatment modalities for nonalcoholic steatohepatitis. Trends in Endocrinology & Metabolism 2010;21:668-75. [DOI: 10.1016/j.tem.2010.08.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
172 Gawrieh S, Chalasani N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:338-48. [PMID: 26378648 DOI: 10.1055/s-0035-1562951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
173 Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2014;5:403-23. [DOI: 10.1586/eem.10.5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
174 Czaja AJ. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:385-406. [PMID: 24387318 DOI: 10.1111/apt.12592] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
175 Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2014;15:1715-1736. [PMID: 24961409 DOI: 10.1517/14656566.2014.931938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
176 Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47:869-880. [PMID: 24004441 DOI: 10.3109/10715762.2013.837577] [Cited by in Crossref: 158] [Cited by in F6Publishing: 146] [Article Influence: 17.6] [Reference Citation Analysis]
177 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1902] [Article Influence: 205.7] [Reference Citation Analysis]
178 Komolafe O, Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJ, Fritche D, Freeman SC, Cooper NJ, Sutton AJ, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;7:CD013157. [PMID: 34280304 DOI: 10.1002/14651858.CD013157.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-? expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007;37:229-35. [DOI: 10.1111/j.1445-5994.2006.01295.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
180 Ivancovsky-Wajcman D, Fliss-Isakov N, Salomone F, Webb M, Shibolet O, Kariv R, Zelber-Sagi S. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. Dig Liver Dis 2019;51:1698-705. [PMID: 31281067 DOI: 10.1016/j.dld.2019.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
181 Parikh N, Ahmad J. Nonalcoholic fatty liver disease: pharmacologic and surgical options. Gastroenterol Clin North Am 2011;40:541-59. [PMID: 21893273 DOI: 10.1016/j.gtc.2011.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
182 Hannah WN, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1365-1374. [PMID: 27052013 DOI: 10.1007/s10620-016-4153-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 10.5] [Reference Citation Analysis]
183 Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2007;4:432-41. [DOI: 10.1038/ncpgasthep0879] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
184 Roberts EA. Non-alcoholic steatohepatitis in children. Clin Liver Dis. 2007;11:155-172, x. [PMID: 17544977 DOI: 10.1016/j.cld.2007.02.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
185 Rickmann M, Vaquero EC, Malagelada JR, Molero X. Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. Gastroenterology. 2007;132:2518-2532. [PMID: 17570223 DOI: 10.1053/j.gastro.2007.03.107] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
186 Abdel-Maboud M, Menshawy A, Menshawy E, Emara A, Alshandidy M, Eid M. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol 2020;13:1756284820974917. [PMID: 33335561 DOI: 10.1177/1756284820974917] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
187 Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.Eur J Gastroenterol Hepatol. 2019;31:613-617. [PMID: 30920975 DOI: 10.1097/MEG.0000000000001369] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
188 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
189 Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4:1537-1543. [PMID: 17162245 DOI: 10.1016/j.cgh.2006.09.025] [Cited by in Crossref: 234] [Cited by in F6Publishing: 216] [Article Influence: 15.6] [Reference Citation Analysis]
190 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
191 Dey A, Lakshmanan J. The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver. Food Funct 2013;4:1148-84. [PMID: 23760593 DOI: 10.1039/c3fo30317a] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 8.9] [Reference Citation Analysis]
192 Kaltenecker D, Themanns M, Mueller KM, Spirk K, Suske T, Merkel O, Kenner L, Luís A, Kozlov A, Haybaeck J, Müller M, Han X, Moriggl R. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. Cytokine 2019;124:154569. [PMID: 30389231 DOI: 10.1016/j.cyto.2018.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
193 Adinolfi LE, Restivo L. Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev Gastroenterol Hepatol. 2011;5:147-150. [PMID: 21476908 DOI: 10.1586/egh.11.27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
194 Polimeni L, Del Ben M, Baratta F, Perri L, Albanese F, Pastori D, Violi F, Angelico F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol 2015; 7(10): 1325-1336 [PMID: 26052378 DOI: 10.4254/wjh.v7.i10.1325] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 14.1] [Reference Citation Analysis]
195 Llibre-Nieto G, Lira A, Vergara M, Solé C, Casas M, Puig-Diví V, Solé G, Humanes A, Grau L, Barradas JM, Miquel M, Sánchez-Delgado J. Micronutrient Deficiencies in Patients with Decompensated Liver Cirrhosis. Nutrients 2021;13:1249. [PMID: 33920134 DOI: 10.3390/nu13041249] [Reference Citation Analysis]
196 Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology 2012;46:272-84. [DOI: 10.1097/mcg.0b013e31824587e0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
197 Yamamoto T, Tomofuji T, Tamaki N, Ekuni D, Azuma T, Sanbe T. Effects of topical application of lipopolysaccharide and proteases on hepatic injury induced by high-cholesterol diet in rats. J Periodontal Res 2010;45:129-35. [PMID: 19602105 DOI: 10.1111/j.1600-0765.2009.01212.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
198 Kim JH, Suk S, Jang WJ, Lee CH, Kim J, Park J, Kweon M, Kim JH, Lee KW. Salicornia Extract Ameliorates Salt-Induced Aggravation of Nonalcoholic Fatty Liver Disease in Obese Mice Fed a High-Fat Diet: Effect of Salicornia -extracted salt…. Journal of Food Science 2017;82:1765-74. [DOI: 10.1111/1750-3841.13777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
199 Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne) 2021;8:595371. [PMID: 33718398 DOI: 10.3389/fmed.2021.595371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
200 Ahmed MH, Byrne CD. Non-Alcoholic Fatty Liver Disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndrome. Oxford: Wiley-Blackwell; 2011. pp. 245-77. [DOI: 10.1002/9781444347319.ch15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
201 Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017;9:E870. [PMID: 28805669 DOI: 10.3390/nu9080870] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
202 Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J 2019;95:601-11. [PMID: 31434683 DOI: 10.1136/postgradmedj-2018-136364] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
203 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1712-1723 [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 73] [Article Influence: 9.8] [Reference Citation Analysis]
204 Weiskirchen R. Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Front Pharmacol. 2015;6:303. [PMID: 26779021 DOI: 10.3389/fphar.2015.00303] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
205 Chaney A. Treating the patient with nonalcoholic fatty liver disease. Nurse Pract 2015;40:36-42; quiz 42-3. [PMID: 26474202 DOI: 10.1097/01.NPR.0000472248.28703.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
207 Diab L, Krebs NF. Vitamin Excess and Deficiency. Pediatrics in Review 2018;39:161-79. [DOI: 10.1542/pir.2016-0068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
208 Aguilera-méndez A, Espino-garcía R, Toledo-lópez ZJ, Hernández-gallegos Z, Villafaña-rauda S, Nieto-aguilar R, Serrato-ochoa D, Manuel-jacobo GC. Biotin improves relaxation of rat aortic rings in combination with antihypertensive drugs. PharmaNutrition 2019;8:100147. [DOI: 10.1016/j.phanu.2019.100147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20. [DOI: 10.1017/s0029665110000030] [Cited by in Crossref: 141] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
210 Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 2014;18:73-89. [DOI: 10.1016/j.cld.2013.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
211 Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta. 2006;364:33-60. [PMID: 16139830 DOI: 10.1016/j.cca.2005.06.014] [Cited by in Crossref: 223] [Cited by in F6Publishing: 232] [Article Influence: 13.1] [Reference Citation Analysis]
212 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 605] [Article Influence: 53.1] [Reference Citation Analysis]
213 Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci. 2016;61:3118-3139. [PMID: 27435327 DOI: 10.1007/s10620-016-4254-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
214 de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104-S112. [PMID: 18304679 DOI: 10.1016/j.jhep.2008.01.009] [Cited by in Crossref: 358] [Cited by in F6Publishing: 349] [Article Influence: 25.6] [Reference Citation Analysis]
215 Akyüz F, Demir K, Özdil S, Aksoy N, Poturoğlu Ş, İbrişim D, Kaymakoğlu S, Beşışık F, Boztaş G, Çakaloğlu Y, Mungan Z, Çevikbaş U, Ökten A. The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2007;52:2359-67. [DOI: 10.1007/s10620-006-9145-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
216 Miyanishi K, Hoki T, Tanaka S, Kato J. Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. World J Hepatol 2015; 7(3): 593-599 [PMID: 25848483 DOI: 10.4254/wjh.v7.i3.593] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
217 Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018;12:331-9. [DOI: 10.1080/17474124.2018.1439379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
218 Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radic Res. 2015;49:1405-1418. [PMID: 26223319 DOI: 10.3109/10715762.2015.1078461] [Cited by in Crossref: 145] [Cited by in F6Publishing: 137] [Article Influence: 20.7] [Reference Citation Analysis]
219 Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci. 2008;53:2246-2250. [PMID: 18049900 DOI: 10.1007/s10620-007-0109-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
220 Bae S, Cho CH, Kim H, Kim Y, Kim HR, Hwang YI, Yoon JH, Kang JS, Lee WJ. In vivo consequence of vitamin C insufficiency in liver injury: vitamin C ameliorates T-cell-mediated acute liver injury in gulo(-/-) mice. Antioxid Redox Signal 2013;19:2040-53. [PMID: 23472641 DOI: 10.1089/ars.2012.4756] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
221 Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med. 2008;44:1259-1272. [PMID: 18242193 DOI: 10.1016/j.freeradbiomed.2007.12.029] [Cited by in Crossref: 291] [Cited by in F6Publishing: 274] [Article Influence: 20.8] [Reference Citation Analysis]
222 Kluwe J, Lohse AW. Therapieoptionen für die nicht-alkoholinduzierte Fettleber und Fettleberhepatitis. Internist 2005;46:1324-30. [DOI: 10.1007/s00108-005-1513-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
223 Day K, Seale LA, Graham RM, Cardoso BR. Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease. Front Nutr 2021;8:744825. [PMID: 34869521 DOI: 10.3389/fnut.2021.744825] [Reference Citation Analysis]
224 Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010;31:62-70. [PMID: 19761871 DOI: 10.1016/j.cct.2009.09.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
225 Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T; NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:472-9. [PMID: 20683947 DOI: 10.1002/hep.23727] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 16.8] [Reference Citation Analysis]
226 Khaldoun Oularbi H, Richeval C, Lebaili N, Zerrouki-Daoudi N, Baha M, Djennas N, Allorge D. Ameliorative effect of vitamin C against hepatotoxicity induced by emamectin benzoate in rats. Hum Exp Toxicol 2017;36:709-17. [PMID: 27461011 DOI: 10.1177/0960327116661022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
227 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
228 Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ, Murad MH, Noureddin M. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:616-629.e26. [PMID: 29913275 DOI: 10.1016/j.cgh.2018.06.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
229 Harrison SA, Neuschwander-tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinics in Liver Disease 2004;8:861-79. [DOI: 10.1016/j.cld.2004.06.008] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]
230 Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science 2008;115:141-50. [DOI: 10.1042/cs20070402] [Cited by in Crossref: 198] [Cited by in F6Publishing: 68] [Article Influence: 14.1] [Reference Citation Analysis]
231 Douglass A, Wallace K, Koruth M, Barelle C, Porter AJ, Wright MC. Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatol Int 2008;2:405-15. [PMID: 19669316 DOI: 10.1007/s12072-008-9093-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
232 Kim SK, Seo JM, Chae YR, Jung YS, Park JH, Kim YC. Alleviation of dimethylnitrosamine-induced liver injury and fibrosis by betaine supplementation in rats. Chemico-Biological Interactions 2009;177:204-11. [DOI: 10.1016/j.cbi.2008.09.021] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
233 Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58. [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011] [Cited by in Crossref: 156] [Cited by in F6Publishing: 142] [Article Influence: 15.6] [Reference Citation Analysis]
234 Suárez M, Boqué N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1052. [PMID: 28937599 DOI: 10.3390/nu9101052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
235 Chande N, Laidlaw M, Adams P, Marotta P. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci 2006;51:1183-9. [PMID: 16944007 DOI: 10.1007/s10620-006-8030-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
236 Ruart M, Chavarria L, Campreciós G, Suárez-herrera N, Montironi C, Guixé-muntet S, Bosch J, Friedman SL, Garcia-pagán JC, Hernández-gea V. Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. Journal of Hepatology 2019;70:458-69. [DOI: 10.1016/j.jhep.2018.10.015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
237 Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-1698. [PMID: 18471547 DOI: 10.1053/j.gastro.2008.02.077] [Cited by in Crossref: 233] [Cited by in F6Publishing: 228] [Article Influence: 16.6] [Reference Citation Analysis]
238 Larion S, Khurana S. Clinical studies investigating the effect of vitamin E therapy in patients with NASH. Clin Liver Dis (Hoboken) 2018;11:16-21. [PMID: 30992781 DOI: 10.1002/cld.687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
239 Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85. [PMID: 20427778 DOI: 10.1056/NEJMoa0907929] [Cited by in Crossref: 1821] [Cited by in F6Publishing: 871] [Article Influence: 151.8] [Reference Citation Analysis]
240 Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:641-648. [PMID: 23075940 DOI: 10.1097/mco.0b013e328357f747] [Cited by in Crossref: 70] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
241 Soylu AR, Aydogdu N, Basaran UN, Altaner S, Tarcin O, Gedik N, Umit H, Tezel A, Dokmeci G, Baloglu H, Ture M, Kutlu K, Kaymak K. Antioxidants vitamin E and C attenuate hepatic fibrosis in biliary-obstructed rats. World J Gastroenterol 2006; 12(42): 6835-6841 [PMID: 17106933 DOI: 10.3748/wjg.v12.i42.6835] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
242 Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021;54:880-9. [PMID: 34435378 DOI: 10.1111/apt.16583] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Bhardwaj P, Madan K, Thareja S, Joshi YK, Saraya A. Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease. Hepatol Int 2008;2:202-8. [PMID: 19669305 DOI: 10.1007/s12072-008-9060-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
244 Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J, Sanhueza E, Contreras J, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol 2014; 20(34): 12182-12201 [PMID: 25232252 DOI: 10.3748/wjg.v20.i34.12182] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
245 Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:36-40. [PMID: 17675901 DOI: 10.1111/j.0197-3118.2006.05523.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
246 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract 2020;35:72-84. [PMID: 31840865 DOI: 10.1002/ncp.10449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
248 David D, Eapen CE. What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? J Clin Exp Hepatol 2021;11:232-8. [PMID: 33746449 DOI: 10.1016/j.jceh.2020.09.001] [Reference Citation Analysis]
249 Budd J, Cusi K. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? Am J Med 2020;133:536-43. [PMID: 32017891 DOI: 10.1016/j.amjmed.2020.01.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
250 Ding Y, Sun X, Chen Y, Deng Y, Qian K. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Eur J Pharmacol 2015;761:405-12. [PMID: 25967348 DOI: 10.1016/j.ejphar.2015.05.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
251 Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Antioxidant supplements for liver diseases. Cochrane Database Syst Rev 2011;:CD007749. [PMID: 21412909 DOI: 10.1002/14651858.CD007749.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
252 Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79-104. [PMID: 20578268 DOI: 10.1002/hep.23623] [Cited by in Crossref: 370] [Cited by in F6Publishing: 343] [Article Influence: 30.8] [Reference Citation Analysis]
253 Raman M, Allard J. Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol 2006;20:345-9. [PMID: 16691301 DOI: 10.1155/2006/918262] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
254 van der Poorten D, George J. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int 2007;1:343-54. [PMID: 19669329 DOI: 10.1007/s12072-007-9011-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
255 Harrison SA, Ward JA, Schenker S. The Role of Vitamin E and C Therapy in NASH. Am J Gastroenterol 2004;99:1862-1862. [DOI: 10.1111/j.1572-0241.2004.40539_3.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
256 Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med. 2008;19:75-82. [PMID: 18249301 DOI: 10.1016/j.ejim.2007.02.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
257 Di Sario A, Candelaresi C, Omenetti A, Benedetti A. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm 2007;76:551-73. [PMID: 17628189 DOI: 10.1016/S0083-6729(07)76021-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
258 Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther 2011; 2(1): 1-5 [PMID: 21577310 DOI: 10.4292/wjgpt.v2.i1.1] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
259 Schreuder TC, Verwer BJ, Nieuwkerk CMV, Mulder CJ. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008; 14(16): 2474-2486 [PMID: 18442193 DOI: 10.3748/wjg.14.2474] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 111] [Article Influence: 8.0] [Reference Citation Analysis]
260 Martínez Soriano B, Güemes A, Pola G, Gonzalo A, Palacios Gasós P, Navarro AC, Martínez-Beamonte R, Osada J, García JJ. Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model. Can J Gastroenterol Hepatol 2020;2020:7315253. [PMID: 32566547 DOI: 10.1155/2020/7315253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
261 Hormoznejad R, Mohammad Shahi M, Rahim F, Helli B, Alavinejad P, Sharhani A. Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial. Int J Food Sci Nutr 2020;71:991-1000. [PMID: 32237922 DOI: 10.1080/09637486.2020.1746957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
262 Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008;CD007176. [PMID: 18425980 DOI: 10.1002/14651858.cd007176] [Cited by in Crossref: 113] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
263 Inoue M, Tazuma S, Kanno K, Hyogo H, Igarashi K, Chayama K. Bach1 gene ablation reduces steatohepatitis in mouse MCD diet model. J Clin Biochem Nutr 2011;48:161-6. [PMID: 21373270 DOI: 10.3164/jcbn.09-122GFR] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
264 Terashima Y, Nishiumi S, Minami A, Kawano Y, Hoshi N, Azuma T, Yoshida M. Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis. Arch Biochem Biophys 2014;555-556:55-65. [PMID: 24857839 DOI: 10.1016/j.abb.2014.05.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
265 Johnson TM, Overgard EB, Cohen AE, Dibaise JK. Nutrition Assessment and Management in Advanced Liver Disease. Nutr Clin Pract 2013;28:15-29. [DOI: 10.1177/0884533612469027] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 10.0] [Reference Citation Analysis]
266 Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-96. [PMID: 19412008 DOI: 10.1097/MPG.0b013e31818e04d1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
267 Hojo M, Watanabe S. Pharmacological therapy of nonalcoholic steatohepatitis: Therapeutic value of NASH treatments. Hepatology Research 2011;41:209-16. [DOI: 10.1111/j.1872-034x.2011.00780.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
268 Wallert M, Börmel L, Lorkowski S. Inflammatory Diseases and Vitamin E-What Do We Know and Where Do We Go? Mol Nutr Food Res 2021;65:e2000097. [PMID: 32692879 DOI: 10.1002/mnfr.202000097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
269 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 15.9] [Reference Citation Analysis]
270 Hsu E, Murray K. Is nonalcoholic fatty liver disease in children the same disease as in adults? Clin Liver Dis 2012;16:587-98. [PMID: 22824482 DOI: 10.1016/j.cld.2012.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
271 Han JM, Jo AN, Lee SM, Bae HS, Jun DW, Cho YK, Suk KT, Yoon JH, Ahn SB, Cho YJ. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2014;29:1265-1272. [PMID: 24955455 DOI: 10.1111/jgh.12520] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
272 Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109-1117. [PMID: 23141876 DOI: 10.1016/j.ijcard.2012.09.085] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
273 Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease: Treatment of NAFLD. International Journal of Clinical Practice 2010;64:968-83. [DOI: 10.1111/j.1742-1241.2009.02327.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
274 Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-6570 [PMID: 29085205 DOI: 10.3748/wjg.v23.i36.6549] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 65] [Article Influence: 16.2] [Reference Citation Analysis]
275 Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, D’Auria MV, Capasso R, Del Vecchio Blanco C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52:2387-2395. [PMID: 17410454 DOI: 10.1007/s10620-006-9703-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
276 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 238] [Article Influence: 24.5] [Reference Citation Analysis]
277 Ekhlasi G, Zarrati M, Agah S, Hosseini AF, Hosseini S, Shidfar S, Soltani Aarbshahi SS, Razmpoosh E, Shidfar F. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. EXCLI J 2017;16:278-90. [PMID: 28507473 DOI: 10.17179/excli2016-846] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
278 Tan H, Chang JP. Non-Alcoholic Fatty Liver Disease. Proceedings of Singapore Healthcare 2010;19:36-50. [DOI: 10.1177/201010581001900106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
279 Tung YT, Huang CZ, Lin JH, Yen GC. Effect of Phyllanthus emblica L. fruit on methionine and choline-deficiency diet-induced nonalcoholic steatohepatitis. J Food Drug Anal 2018;26:1245-52. [PMID: 30249323 DOI: 10.1016/j.jfda.2017.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
280 Jhummon NP, Tohooloo B, Qu S. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave's disease. Thyroid Res 2013;6:4. [PMID: 23497434 DOI: 10.1186/1756-6614-6-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
281 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
282 Zhang C, Ding Z, Suhaimi NA, Kng YL, Zhang Y, Zhuo L. A class of imidazolium salts is anti-oxidative and anti-fibrotic in hepatic stellate cells. Free Radic Res 2009;43:899-912. [PMID: 19670067 DOI: 10.1080/10715760903137002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
283 Ross AB, Godin JP, Minehira K, Kirwan JP. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol. 2013;2013:585876. [PMID: 23762052 DOI: 10.1155/2013/585876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
284 Cernea S, Cahn A, Raz I. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Rev Clin Pharmacol. 2017;10:535-547. [PMID: 28276774 DOI: 10.1080/17512433.2017.1300059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
285 Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278. [PMID: 19353360 DOI: 10.1080/07853890802552437] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
286 Cho T, Kim YJ, Paik SS. The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 2012;15:256-265. [PMID: 24010096 DOI: 10.5223/pghn.2012.15.4.256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
287 Nguyen TA, Sanyal AJ. Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2012;27 Suppl 2:58-64. [PMID: 22320918 DOI: 10.1111/j.1440-1746.2011.07018.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
288 Ipsen DH, Tveden-Nyborg P, Lykkesfeldt J. Does vitamin C deficiency promote fatty liver disease development? Nutrients 2014;6:5473-99. [PMID: 25533004 DOI: 10.3390/nu6125473] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
289 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123:1887-1901. [PMID: 23635787 DOI: 10.1172/jci66028] [Cited by in Crossref: 393] [Cited by in F6Publishing: 226] [Article Influence: 43.7] [Reference Citation Analysis]
290 Tatsumi K, Sasaki H, Fujita A, Doi A, Kanaya Y, Furuta H, Nishi M, Tsuno T, Taniguchi H, Nanjo K. Effect of anti-oxidants, Ricetrienol and α-tocopherol, on adipocytokine abnormalities and fatty liver in Otsuka Long-Evans Tokushima Fatty diabetic rats. J Diabetes Investig 2011;2:186-92. [PMID: 24843482 DOI: 10.1111/j.2040-1124.2010.00090.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
291 Gujjala S, Putakala M, Ramaswamy R, Desireddy S. Preventive effect of Caralluma fimbriata vs. Metformin against high-fat diet-induced alterations in lipid metabolism in Wistar rats. Biomedicine & Pharmacotherapy 2016;84:215-23. [DOI: 10.1016/j.biopha.2016.09.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
292 He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, Huang ZM. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11:e0162368. [PMID: 27711128 DOI: 10.1371/journal.pone.0162368] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
293 Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-1058. [PMID: 15625647 DOI: 10.1016/s1542-3565(04)00440-9] [Cited by in Crossref: 255] [Cited by in F6Publishing: 113] [Article Influence: 15.0] [Reference Citation Analysis]
294 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 1009] [Article Influence: 107.8] [Reference Citation Analysis]
295 Ackerman Z, Oron-herman M, Rosenthal T, Pappo O, Link G, Sela B, Grozovski M. Effects of Amlodipine, Captopril, and Bezafibrate on Oxidative Milieu in Rats with Fatty Liver. Dig Dis Sci 2008;53:777-84. [DOI: 10.1007/s10620-007-9911-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
296 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
297 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112. [PMID: 16447287 DOI: 10.1002/hep.20973] [Cited by in Crossref: 1618] [Cited by in F6Publishing: 1564] [Article Influence: 101.1] [Reference Citation Analysis]
298 Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863-869. [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 13.1] [Reference Citation Analysis]
299 Heskett CW, Teafatiller T, Hennessey C, Gareau MG, Marchant JS, Said HM, Subramanian VS. Enteropathogenic Escherichia coli Infection Inhibits Intestinal Ascorbic Acid Uptake via Dysregulation of Its Transporter Expression. Dig Dis Sci 2021;66:2250-60. [PMID: 32556816 DOI: 10.1007/s10620-020-06389-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
300 Townsend SA, Newsome PN. Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:494-507. [PMID: 28677333 DOI: 10.1111/apt.14210] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
301 Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients 2021;13:2830. [PMID: 34444990 DOI: 10.3390/nu13082830] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2010;1:101-115. [PMID: 23148155 DOI: 10.1177/2042018810379587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
303 Raza S, Tewari A, Rajak S, Sinha RA. Vitamins and non-alcoholic fatty liver disease: A Molecular Insight. Liver Res 2021;5:62-71. [PMID: 34221537 DOI: 10.1016/j.livres.2021.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
304 Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien P. Serotonin Mediates Oxidative Stress and Mitochondrial Toxicity in a Murine Model of Nonalcoholic Steatohepatitis. Gastroenterology 2007;133:608-18. [DOI: 10.1053/j.gastro.2007.05.019] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 6.7] [Reference Citation Analysis]
305 Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, Chaiyakunapruk N. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016;95:e4529. [PMID: 27512874 DOI: 10.1097/md.0000000000004529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
306 Ullah R, Rauf N, Nabi G, Ullah H, Shen Y, Zhou YD, Fu J. Role of Nutrition in the Pathogenesis and Prevention of Non-alcoholic Fatty Liver Disease: Recent Updates. Int J Biol Sci 2019;15:265-76. [PMID: 30745819 DOI: 10.7150/ijbs.30121] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
307 Tariq Z, Green CJ, Hodson L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Liver Int 2014;34:e180-90. [DOI: 10.1111/liv.12523] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
308 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
309 Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis. 2016;20:225-243. [PMID: 27063266 DOI: 10.1016/j.cld.2015.10.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
310 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Role of Vitamin E in the Treatment of NAFLD. Diseases 2018;6:E86. [PMID: 30249972 DOI: 10.3390/diseases6040086] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
311 Gandhi N, Lenton R, Bhartia M, Abbas A, Raju J, Ramachandran S. Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus. 2014;3:14. [PMID: 24455467 DOI: 10.1186/2193-1801-3-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
312 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(13): 3777-3785 [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 68] [Article Influence: 9.9] [Reference Citation Analysis]
313 Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011;5:279-89. [PMID: 21476922 DOI: 10.1586/egh.11.19] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
314 Kadayifci A, Merriman RB, Bass NM. Medical Treatment of Non-alcoholic Steatohepatitis. Clinics in Liver Disease 2007;11:119-40. [DOI: 10.1016/j.cld.2007.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
315 Dou X, Li S, Hu L, Ding L, Ma Y, Ma W, Chai H, Song Z. Glutathione disulfide sensitizes hepatocytes to TNFα-mediated cytotoxicity via IKK-β S-glutathionylation: a potential mechanism underlying non-alcoholic fatty liver disease. Exp Mol Med 2018;50:1-16. [PMID: 29622764 DOI: 10.1038/s12276-017-0013-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
316 Jurak M, Miñones Conde J. Characterization of the binary mixed monolayers of α-tocopherol with phospholipids at the air-water interface. Biochimica et Biophysica Acta (BBA) - Biomembranes 2013;1828:2410-8. [DOI: 10.1016/j.bbamem.2013.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
317 Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs 2011;16:121-36. [PMID: 21352073 DOI: 10.1517/14728214.2011.531700] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
318 Kawanaka M, Nishino K, Nakamura J, Suehiro M, Goto D, Urata N, Oka T, Kawamoto H, Nakamura H, Yodoi J. Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study. Hepat Med. 2013;5:11-16. [PMID: 24695939 DOI: 10.2147/hmer.s41258] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
319 Bataller R, Sancho-Bru P, Ginès P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal. 2005;7:1346-1355. [PMID: 16115040 DOI: 10.1089/ars.2005.7.1346] [Cited by in Crossref: 111] [Cited by in F6Publishing: 110] [Article Influence: 6.9] [Reference Citation Analysis]
320 Bernal C, Martín-pozuelo G, Lozano AB, Sevilla Á, García-alonso J, Canovas M, Periago MJ. Lipid biomarkers and metabolic effects of lycopene from tomato juice on liver of rats with induced hepatic steatosis. The Journal of Nutritional Biochemistry 2013;24:1870-81. [DOI: 10.1016/j.jnutbio.2013.05.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
321 Colak Y, Tuncer I, Senates E, Ozturk O, Doganay L, Yilmaz Y. Nonalcoholic Fatty Liver Disease: A Nutritional Approach. Metabolic Syndrome and Related Disorders 2012;10:161-6. [DOI: 10.1089/met.2011.0145] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
322 Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008;47:746-54. [DOI: 10.1002/hep.22009] [Cited by in Crossref: 158] [Cited by in F6Publishing: 154] [Article Influence: 10.5] [Reference Citation Analysis]
323 Wei J, Lei GH, Fu L, Zeng C, Yang T, Peng SF. Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults. PLoS One 2016;11:e0147985. [PMID: 26824361 DOI: 10.1371/journal.pone.0147985] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
324 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 343] [Article Influence: 36.6] [Reference Citation Analysis]
325 Botchlett R, Wu C. Diet Composition for the Management of Obesity and Obesity-related Disorders. J Diabetes Mellit Metab Syndr 2018;3:10-25. [PMID: 30972384 DOI: 10.28967/jdmms.2018.01.18002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
326 Kaya V, Yazkan R, Yıldırım M, Doğuç DK, Süren D, Bozkurt KK, Yüksel Ö, Demırpence Ö, Şen CA, Yalçın AY. The relation of radiation-induced pulmonary fibrosis with stress and the efficiency of antioxidant treatment: an experimental study. Med Sci Monit 2014;20:290-6. [PMID: 24556959 DOI: 10.12659/MSM.890334] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
327 Salehi-Sahlabadi A, Sadat S, Beigrezaei S, Pourmasomi M, Feizi A, Ghiasvand R, Hadi A, Clark CCT, Miraghajani M. Dietary patterns and risk of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:41. [PMID: 33509112 DOI: 10.1186/s12876-021-01612-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
328 Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: REVIEW: CURRENT MANAGEMENT OF NAFLD AND NASH. Alimentary Pharmacology & Therapeutics 2008;28:2-12. [DOI: 10.1111/j.1365-2036.2008.03710.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
329 Czaja AJ. Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis. Dig Dis Sci 2016;61:2784-803. [PMID: 27411555 DOI: 10.1007/s10620-016-4247-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
330 Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 2012;56:448-54. [PMID: 21756849 DOI: 10.1016/j.jhep.2011.05.029] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 9.7] [Reference Citation Analysis]
331 Ganji SH, Kukes GD, Lambrecht N, Kashyap ML, Kamanna VS. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2014;306:G320-G327. [PMID: 24356885 DOI: 10.1152/ajpgi.00181.2013] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
332 Cortez-pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: From cell biology to clinical practice. Journal of Hepatology 2006;44:197-208. [DOI: 10.1016/j.jhep.2005.09.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 129] [Article Influence: 8.7] [Reference Citation Analysis]
333 Federico A, Trappoliere M, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig Liver Dis. 2006;38:789-801. [PMID: 16750661 DOI: 10.1016/j.dld.2006.04.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
334 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
335 Strahl S, Maier KP. [Are there therapeutic approaches of non-alcoholic fatty liver disease and its complications?]. Internist (Berl) 2008;49:1421-2, 1424-7. [PMID: 19002423 DOI: 10.1007/s00108-008-2151-7] [Reference Citation Analysis]
336 Liu X, Peng Y, Chen S, Sun Q. An observational study on the association between major dietary patterns and non-alcoholic fatty liver disease in Chinese adolescents. Medicine (Baltimore) 2018;97:e0576. [PMID: 29703050 DOI: 10.1097/MD.0000000000010576] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
337 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
338 Baselga-escudero L, Souza-mello V, Pascual-serrano A, Rachid T, Voci A, Demori I, Grasselli E. Beneficial effects of the Mediterranean spices and aromas on non-alcoholic fatty liver disease. Trends in Food Science & Technology 2017;61:141-59. [DOI: 10.1016/j.tifs.2016.11.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
339 O'Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005;9:103-34. [PMID: 15763232 DOI: 10.1016/j.cld.2004.11.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
340 Nobili V, Sanyal AJ. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol 2012;47:29-36. [PMID: 21983927 DOI: 10.1007/s00535-011-0467-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
341 Jothery AH, Vaanholt LM, Mody N, Arnous A, Lykkesfeldt J, Bünger L, Hill WG, Mitchell SE, Allison DB, Speakman JR. Oxidative costs of reproduction in mouse strains selected for different levels of food intake and which differ in reproductive performance. Sci Rep 2016;6:36353. [PMID: 27841266 DOI: 10.1038/srep36353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
342 Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-9. [PMID: 19501928 DOI: 10.1016/j.jhep.2009.03.019] [Cited by in Crossref: 353] [Cited by in F6Publishing: 335] [Article Influence: 27.2] [Reference Citation Analysis]
343 Robinson KE, Shah VH. Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2020;5:49. [PMID: 33073044 DOI: 10.21037/tgh.2019.12.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
344 Poulos JE, Kalogerinis PT, Milanov V, Kalogerinis CT, Poulos EJ. The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease. J Diet Suppl 2021;:1-16. [PMID: 33491528 DOI: 10.1080/19390211.2021.1874587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
345 Chung GE, Youn J, Kim YS, Lee JE, Yang SY, Lim JH, Song JH, Doo EY, Kim JS. Dietary patterns are associated with the prevalence of nonalcoholic fatty liver disease in Korean adults. Nutrition 2019;62:32-8. [DOI: 10.1016/j.nut.2018.11.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
346 Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol. 2014;20:143-153. [PMID: 24976277 DOI: 10.4103/1319-3767.132983] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
347 Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990-994. [PMID: 19448566 DOI: 10.1097/mcg.0b013e31819c392e] [Cited by in Crossref: 177] [Cited by in F6Publishing: 70] [Article Influence: 14.8] [Reference Citation Analysis]
348 Federico A, Niosi M, Vecchio Blanco CD, Loguercio C. Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008;13:145-158. [PMID: 18321154 DOI: 10.1517/14728214.13.1.145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
349 Chavez-Tapia NC, Sanchez-Avila F, Vasquez-Fernandez F, Torres-Machorro A, Tellez-Avila FI, Uribe M. Non-alcoholic fatty-liver disease in pediatric populations. J Pediatr Endocrinol Metab 2007;20:1059-73. [PMID: 18051925 DOI: 10.1515/jpem.2007.20.10.1059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
350 Del Ben M, Polimeni L, Baratta F, Pastori D, Angelico F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol. 2017;83:88-95. [PMID: 26852185 DOI: 10.1111/bcp.12899] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
351 Selmi C, Bowlus CL, Keen CL, Gershwin ME. Non-alcoholic fatty liver disease: the new epidemic and the need for novel nutritional approaches. J Med Food 2007;10:563-5. [PMID: 18158823 DOI: 10.1089/jmf.2007.620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
352 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(3): 367-370 [DOI: 10.11569/wcjd.v13.i3.367] [Reference Citation Analysis]
353 Lombardi R, Iuculano F, Pallini G, Fargion S, Fracanzani AL. Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. Int J Mol Sci 2020;21:E8761. [PMID: 33228237 DOI: 10.3390/ijms21228761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
354 Saadeh S. Nonalcoholic Fatty liver disease and obesity. Nutr Clin Pract. 2007;22:1-10. [PMID: 17242448 DOI: 10.1177/011542650702200101] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
355 Al-Busafi SA, Bhat M, Wong P, Ghali P, Deschenes M. Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat. 2012;2012:947575. [PMID: 23227320 DOI: 10.1155/2012/947575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
356 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 16.6] [Reference Citation Analysis]
357 Tojima H, Kakizaki S, Kosone T, Horiguchi N, Yamazaki Y, Sato K, Takagi H, Mori M. Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatol Int 2012;6:620-30. [DOI: 10.1007/s12072-011-9301-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
358 Ahmad A, Afroz N, Gupta UD, Ahmad R. Vitamin B 12 supplement alleviates N ′-nitrosodimethylamine-induced hepatic fibrosis in rats. Pharmaceutical Biology 2013;52:516-23. [DOI: 10.3109/13880209.2013.864682] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
359 Barrera F, George J. The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD. Clinics in Liver Disease 2014;18:91-112. [DOI: 10.1016/j.cld.2013.09.009] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
360 Liu L, Hong W, Li M, Ren H, Wang J, Xu H, Shi X, Xu Y. A Cross Talk Between BRG1 and Males Absent on the First Contributes to Reactive Oxygen Species Production in a Mouse Model of Nonalcoholic Steatohepatitis. Antioxid Redox Signal 2019;30:1539-52. [PMID: 29963902 DOI: 10.1089/ars.2016.6822] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
361 Watanabe M, Fuda H, Jin S, Sakurai T, Hui S, Takeda S, Watanabe T, Koike T, Chiba H. A phenolic antioxidant from the Pacific oyster (Crassostrea gigas) inhibits oxidation of cultured human hepatocytes mediated by diphenyl-1-pyrenylphosphine. Food Chemistry 2012;134:2086-9. [DOI: 10.1016/j.foodchem.2012.04.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
362 de Piano A, Tock L, Carnier J, Foschini D, Sanches Pde L, Corrêa FA, Oyama LM, do Nascimento CM, Lederman HM, Ernandes R, de Mello MT, Tufik S, Dâmaso A. The role of nutritional profile in the orexigenic neuropeptide secretion in nonalcoholic fatty liver disease obese adolescents. Eur J Gastroenterol Hepatol 2010;22:557-63. [PMID: 20164781 DOI: 10.1097/MEG.0b013e3283346df2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
363 Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(19): 2083-2094 [PMID: 29785077 DOI: 10.3748/wjg.v24.i19.2083] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
364 Park SH. [Nonalcoholic steatohepatitis: pathogenesis and treatment]. Korean J Hepatol 2008;14:12-27. [PMID: 18367854 DOI: 10.3350/kjhep.2008.14.1.12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
365 Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2011;15:1325-1365. [PMID: 20969475 DOI: 10.1089/ars.2009.3058] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 8.8] [Reference Citation Analysis]
366 Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2021;160:912-8. [PMID: 33307021 DOI: 10.1053/j.gastro.2020.11.051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
367 Subramanian VS, Sabui S, Moradi H, Marchant JS, Said HM. Inhibition of intestinal ascorbic acid uptake by lipopolysaccharide is mediated via transcriptional mechanisms. Biochim Biophys Acta Biomembr 2018;1860:556-65. [PMID: 29030247 DOI: 10.1016/j.bbamem.2017.10.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
368 Cobo Martín M, Fernández Gil P, Crespo J. [Treatment of fatty liver disease]. Gastroenterol Hepatol 2008;31:229-38. [PMID: 18405489 DOI: 10.1157/13117902] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
369 Anderson N, Borlak J. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacol Rev 2008;60:311-57. [DOI: 10.1124/pr.108.00001] [Cited by in Crossref: 260] [Cited by in F6Publishing: 249] [Article Influence: 18.6] [Reference Citation Analysis]
370 Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, Häussinger D. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). Eur J Med Res. 2011;16:76-78. [PMID: 21463986 DOI: 10.1186/2047-783x-16-2-76] [Cited by in Crossref: 82] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
371 Stefano JT, Cogliati B, Santos F, Lima VM, Mazo DC, Matte U, Alvares-da-Silva MR, Silveira TR, Carrilho FJ, Oliveira CP. S-Nitroso-N-acetylcysteine induces de-differentiation of activated hepatic stellate cells and promotes antifibrotic effects in vitro. Nitric Oxide 2011;25:360-5. [PMID: 21820071 DOI: 10.1016/j.niox.2011.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
372 Torres DM, Harrison SA. Current treatments in nonalcoholic steatohepatitis. Curr Treat Options Gastro 2007;10:425-34. [DOI: 10.1007/s11938-007-0042-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
373 Harrison SA. Liver Disease in Patients With Diabetes Mellitus. Journal of Clinical Gastroenterology 2006;40:68-76. [DOI: 10.1097/01.mcg.0000190774.91875.d2] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 7.8] [Reference Citation Analysis]
374 Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011;31:1432-1448. [PMID: 22093324 DOI: 10.1111/j.1478-3231.2011.02604.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 109] [Article Influence: 11.7] [Reference Citation Analysis]
375 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
376 Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medicines for fatty liver diseases. Cochrane Database Syst Rev. 2013;(8):CD009059. [PMID: 23975682 DOI: 10.1002/14651858.cd009059.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
377 Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50:171-180. [PMID: 15712657 DOI: 10.1007/s10620-005-1267-z] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 9.8] [Reference Citation Analysis]
378 Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33. [DOI: 10.1111/j.1464-5491.2005.01748.x] [Cited by in Crossref: 193] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
379 Ong JP, Younossi ZM. Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2005;9:617-34. [DOI: 10.1016/j.cld.2005.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
380 Yan M, Wang J, Xuan Q, Dong T, He J, Zhang Q. The Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early-stage Breast Cancer. Clinical Breast Cancer 2017;17:195-203. [DOI: 10.1016/j.clbc.2016.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
381 Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Rev Gastroenterol Hepatol. 2008;2:59-79. [PMID: 19072371 DOI: 10.1586/17474124.2.1.59] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
382 Bloomgarden ZT. Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance. Metabolic Syndrome and Related Disorders 2005;3:316-27. [DOI: 10.1089/met.2005.3.316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
383 Ratziu V, Vispo M, Tahiri M, Bonyhay L, de Torres M, Bernhardt C, Poynard T, Lebray P. Peut-on traiter la stéatohépatite métabolique ? Gastroentérologie Clinique et Biologique 2007;31:333-40. [DOI: 10.1016/s0399-8320(07)89386-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
384 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
385 Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 2010;30:795-808. [PMID: 20624207 DOI: 10.1111/j.1478-3231.2010.02264.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
386 Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;CD007176. [PMID: 22419320 DOI: 10.1002/14651858.cd007176.pub2] [Cited by in Crossref: 163] [Cited by in F6Publishing: 179] [Article Influence: 16.3] [Reference Citation Analysis]
387 Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-8. [PMID: 15352910 DOI: 10.1111/j.1365-2036.2004.02153.x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 107] [Article Influence: 6.8] [Reference Citation Analysis]
388 Godos J, Federico A, Dallio M, Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. Int J Food Sci Nutr. 2017;68:18-27. [PMID: 27484357 DOI: 10.1080/09637486.2016.1214239] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
389 Lee DH, Jung YY, Park MH, Jo MR, Han SB, Yoon DY, Roh YS, Hong JT. Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function. Antioxidants & Redox Signaling 2019;31:387-402. [DOI: 10.1089/ars.2018.7544] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
390 Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD004996. [PMID: 17253535 DOI: 10.1002/14651858.CD004996.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
391 Enosawa S, Dozen M, Tada Y, Hirasawa K. Electron Therapy Attenuated Elevated Alanine Aminotransferase and Oxidative Stress Values in Type 2 Diabetes-Induced Nonalcoholic Steatohepatitis of Rats. Cell Med 2013;6:63-73. [PMID: 26858882 DOI: 10.3727/215517913X674225] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
392 Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88-96. [PMID: 18804555 DOI: 10.1016/j.cct.2008.09.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 7.5] [Reference Citation Analysis]
393 Nan YM, Wu WJ, Fu N, Liang BL, Wang RQ, Li LX, Zhao SX, Zhao JM, Yu J. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol. 2009;44:1121-1131. [PMID: 19606393 DOI: 10.1080/00365520903114912] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
394 Yang CQ, Shu L, Wang S, Wang JJ, Zhou Y, Xuan YJ, Wang SF. Dietary Patterns Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Chinese Adults. Nutrients 2015;7:4778-91. [PMID: 26083112 DOI: 10.3390/nu7064778] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
395 Curcio A, Romano A, Cuozzo S, Nicola AD, Grassi O, Schiaroli D, Nocera GF, Pironti M. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. Medicina (Kaunas) 2020;56:E544. [PMID: 33080906 DOI: 10.3390/medicina56100544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
396 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1822] [Article Influence: 395.6] [Reference Citation Analysis]
397 Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005;54:987-993. [PMID: 15951547 DOI: 10.1136/gut.2004.057968] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 7.9] [Reference Citation Analysis]
398 Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis. 2004;8:549-558, viii. [PMID: 15331063 DOI: 10.1016/j.cld.2004.04.010] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 7.3] [Reference Citation Analysis]
399 Della Pepa G, Vetrani C, Lombardi G, Bozzetto L, Annuzzi G, Rivellese AA. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. Nutrients 2017;9:E1065. [PMID: 28954437 DOI: 10.3390/nu9101065] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
400 Coelho JM, Cansanção K, Perez RM, Leite NC, Padilha P, Ramalho A, Peres W. Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study. PeerJ 2020;8:e9838. [PMID: 32995080 DOI: 10.7717/peerj.9838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
401 Putakala M, Gujjala S, Nukala S, Desireddy S. Beneficial Effects of Phyllanthus amarus Against High Fructose Diet Induced Insulin Resistance and Hepatic Oxidative Stress in Male Wistar Rats. Appl Biochem Biotechnol 2017;183:744-64. [PMID: 28353042 DOI: 10.1007/s12010-017-2461-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
402 Della Corte C, Alisi A, Iorio R, Alterio A, Nobili V. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opin Pharmacother. 2011;12:1901-1911. [PMID: 21639814 DOI: 10.1517/14656566.2011.587123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
403 Chen MM, Cai JJ, Yu Y, She ZG, Li H. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. Gene Expr 2019;19:175-85. [PMID: 30940296 DOI: 10.3727/105221619X15536120524171] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
404 Subramanian VS, Nabokina SM, Patton JR, Marchant JS, Moradi H, Said HM. Glyoxalate reductase/hydroxypyruvate reductase interacts with the sodium-dependent vitamin C transporter-1 to regulate cellular vitamin C homeostasis. Am J Physiol Gastrointest Liver Physiol 2013;304:G1079-86. [PMID: 23599041 DOI: 10.1152/ajpgi.00090.2013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
405 Bahri S, Abdennabi R, Mlika M, Neji G, Jameleddine S, Ali RB. Effect of Phoenix dactylifera L. Sap Against Bleomycin-Induced Pulmonary Fibrosis and Oxidative Stress in Rats: Phytochemical and Therapeutic Assessment. Nutrition and Cancer 2019;71:781-91. [DOI: 10.1080/01635581.2018.1521442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
406 Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr. 2006;43:413-427. [PMID: 17033514 DOI: 10.1097/01.mpg.0000239995.58388.56] [Cited by in Crossref: 164] [Cited by in F6Publishing: 150] [Article Influence: 10.3] [Reference Citation Analysis]
407 Kwak DS, Jun DW, Seo JG, Chung WS, Park SE, Lee KN, Khalid-Saeed W, Lee HL, Lee OY, Yoon BC, Choi HS. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. Eur J Gastroenterol Hepatol 2014;26:1353-9. [PMID: 25244414 DOI: 10.1097/MEG.0000000000000214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
408 Vilar‐gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N. Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology 2019;71:495-509. [DOI: 10.1002/hep.30368] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
409 Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol. 2003;98:2348-2350. [PMID: 14638333 DOI: 10.1111/j.1572-0241.2003.08695.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
410 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
411 Pickett-Blakely O, Young K, Carr RM. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cell Mol Gastroenterol Hepatol. 2018;6:451-462. [PMID: 30294653 DOI: 10.1016/j.jcmgh.2018.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
412 Chanu Thounaojam M, Navalsinh Jadeja R, Devkar RV, Vadathala Ramachandran A. Non-alcoholic steatohepatitis: an overview including treatments with herbals as alternative therapeutics. J Appl Biomed 2012;10:119-36. [DOI: 10.2478/v10136-012-0008-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
413 Chen YY, Yeh MM. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. J Formos Med Assoc 2021;120:68-77. [PMID: 32654868 DOI: 10.1016/j.jfma.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
414 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661. [PMID: 19834957 DOI: 10.1002/cncr.24687] [Cited by in Crossref: 257] [Cited by in F6Publishing: 239] [Article Influence: 21.4] [Reference Citation Analysis]
415 Park E, Giacca A. Mechanisms underlying fat-induced hepatic insulin resistance. Future Lipidology 2007;2:503-12. [DOI: 10.2217/17460875.2.5.503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
416 Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World J Gastroenterol 2011; 17(29): 3377-3389 [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377] [Cited by in CrossRef: 158] [Cited by in F6Publishing: 152] [Article Influence: 14.4] [Reference Citation Analysis]